Reposicionamento in silico de novos fármacos contra o schistosoma mansoni

• Autor(a) principal: Arantes, Morgana Elias
• Data de Publicação: 2016
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/001300000b90t
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/6003
• topic: Controle; Schistosoma mansoni; Reposicionamento de fármacos; Bioinformática; Control; Schistosoma mansoni; Drug repositioning; Bioinformatics; CIENCIAS BIOLOGICAS::PARASITOLOGIA

Schistosomiasis is a neglected tropical disease caused by parasites of the genus Schistosoma. In Brazil only Schistosoma mansoni transmits this disease. The World Health Organization estimated in 2012 approximately 249 million people at risk of acquiring this disease around the world. The main strategy to control this disease is the treatment of individuals living in endemic areas with Praziquantel. The drug praziquantel is used on a large scale in the treatment of schistosomiasis and currently there are reported cases of resistance, indicating the need to discover new drugs. In silico drug repositioning is a strategy that reduces the time and cost in the search of anti-schistosomal agents. This work used bioinformatics tools and methodology based on previous studies, as a means to identify potential new S. mansoni targets and drug homologs, consequently identifying potential new schistosomal drugs. A list was compiled with S. mansoni potential targets that are part of essential processes in the database TDR and the targets that are part of the tegument were obtained in the scientific literature. The file with S. mansoni targets contained 1376 targets, and of these only 61 targets associated with 399 drugs had homology with drug targets. After removal of duplicate drugs, drugs found in previous studies and after the analysis of the conservation of the active site only 28 S. mansoni targets associated with 102 drugs had 60% or more of the active site conserved. Some of the drugs had activity and are interesting to validate this study such as: artemether, lumefantrine, meloxicam. Among the drugs found 18 drugs were selected to be tested using the following criteria: low toxicity in vivo, expired patent and a value of log P interesting for oral administration.